Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Regorafenib (Primary) ; Clobetasol
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms ReDOS
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
- 25 Jan 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2020.